Surveying the next 12 months, J&J expects to chart roughly 3% sales growth to $91.3 billion in 2025 by “overcoming headwinds associated with U.S. biosimilar entries for Stelara,” as well as ...

Biosimilars continue to gain influence. A comprehensive biosimilar chart featured in the Outlook includes 24 molecules with corresponding FDA-approved biosimilar products, future pipeline products ...

The US is India’s largest export market for pharmaceuticals, accounting for over 30% of overall pharma exports in FY23-24 at ...

Perceive Pharma, a pharmaceutical company pioneering novel small molecule therapeutics in ophthalmology, today announced the closing of a $15M Series A funding round including Deerfield Management, ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...